Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lessened its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 72.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 134,518 shares of the company’s stock after selling 348,746 shares during the period. Commonwealth Equity Services LLC owned 0.21% of Galectin Therapeutics worth $174,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in GALT. Barclays PLC grew its holdings in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after purchasing an additional 21,598 shares during the last quarter. Stratos Wealth Partners LTD. boosted its position in shares of Galectin Therapeutics by 27.4% in the 4th quarter. Stratos Wealth Partners LTD. now owns 51,550 shares of the company’s stock valued at $66,000 after purchasing an additional 11,100 shares during the period. Geode Capital Management LLC grew its stake in Galectin Therapeutics by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock worth $2,372,000 after buying an additional 20,817 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Galectin Therapeutics by 46.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,369 shares of the company’s stock worth $66,000 after buying an additional 16,271 shares during the period. Finally, State Street Corp lifted its stake in Galectin Therapeutics by 9.3% in the third quarter. State Street Corp now owns 251,014 shares of the company’s stock valued at $690,000 after buying an additional 21,399 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Stock Down 5.1 %

Shares of GALT opened at $1.29 on Friday. The company has a market capitalization of $81.50 million, a PE ratio of -1.77 and a beta of 0.79. Galectin Therapeutics Inc. has a 52-week low of $0.73 and a 52-week high of $4.27. The company has a 50-day simple moving average of $1.47 and a 200-day simple moving average of $1.88.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Monday, March 31st. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). On average, research analysts anticipate that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on GALT shares. HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a research note on Wednesday, April 2nd. StockNews.com cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 30th.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.